MITHRA ANNOUNCES 2017 HALF YEAR RESULTS
FTSE 250, industry-leading device & formulation business for inhaled airways disease
Our senior team has worked together for many years, delivering high-level strategic healthcare consultancy with seamless execution and unrivalled market intelligence.
Consilium Healthcare - RT @MedDayPharm: We are at #dgnkongress! Drop by and see us at Booth No.D5 #MS #multiplesclerosis https://t.co/6A3GJxIyfv